December 10, 2020
Failure of samples to meet dissolution specifications has prompted Torrent Pharma Inc. to voluntarily recall nearly 2500 bottles of anagrelide capsules, according to the December 9, 2020, US Food and Drug Administration (FDA) Enforcement Report.
The recall affects 100-count anagrelide capsules, 1 mg (NDC 13668-462-01), from batch BFD1G001 (Exp. 12/21). The capsules were manufactured in India for Torrent Pharma and distributed throughout the United States and in Puerto Rico.
Torrent Pharma initiated the recall November 25, 2020. At press time, the FDA had not yet classified the recall.
Anagrelide is a prescription blood thinner indicated for the treatment of patients with thrombocythemia.